Finasteride Tablet, Film Coated
Product Images NDC 70518-1704

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 70518-1704). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Finasteride 5mg 70518 1704 01 (1)

Label for Finasteride 5 mg film-coated tablets, oral use, from RemedyRepack Inc. The label notes a quantity of 90 tablets and includes prescription-only status, NDC 70518-1704-01, manufacturer information (Rising Pharma, Inc., NJ), along with storage instructions and safety warnings. A barcode and QR code are also visible.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' comparing mean change from baseline over four years for Finasteride versus placebo groups. The y-axis shows mean change from baseline ±1 SE, with values from 0 to -6. The x-axis shows time points: Baseline, Year 1, Year 2, Year 3, and Year 4. Two lines represent symptom scores for placebo and Finasteride groups with sample sizes noted below each year.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP' showing the cumulative percentage of patients over 48 months. It compares Finasteride and Placebo groups, with axes labeled as Percent of Patients (vertical) and Observation Time in Months (horizontal). The graph shows lower surgery percentages in the Finasteride group throughout the observation period. Below the graph, tables present cumulative number of events and numbers at risk per year for both groups.*

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Finasteride Fig3)

A line graph titled "Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)" comparing Finasteride and Placebo groups over 48 months. The x-axis shows observation time in months; the y-axis shows percent of patients developing this condition. The Finasteride group shows a lower cumulative percentage compared to Placebo. A table below lists cumulative events and patients at risk per year for both groups.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Finasteride Fig4)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline over four years. Two data series compare placebo and finasteride groups, with prostate volume increasing in the placebo group and decreasing in the finasteride group over time. Sample sizes at baseline and each year are noted for both groups.*

FDA Label Image

Finasteride Fig5

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing percent with event on the y-axis and years from randomization on the x-axis. Four treatment groups are plotted: Placebo, Finasteride, Doxazosin, and Combination, each with distinct line markers illustrating their cumulative incidence trends over approximately 5.5 years.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of Finasteride, depicting its steroidal framework with characteristic functional groups including a lactam and tert-butyl moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.